160 related articles for article (PubMed ID: 37584729)
41. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
42. Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients.
Chen P; Zhang G; Zhou Q; Li Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32639004
[TBL] [Abstract][Full Text] [Related]
43. Association between temporal muscle thickness and clinical outcomes in patients with newly diagnosed glioblastoma.
An G; Ahn S; Park JS; Jeun SS; Hong YK
J Cancer Res Clin Oncol; 2021 Mar; 147(3):901-909. PubMed ID: 32929611
[TBL] [Abstract][Full Text] [Related]
44. Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.
Pessina F; Navarria P; Cozzi L; Tomatis S; Riva M; Ascolese AM; Santoro A; Simonelli M; Bello L; Scorsetti M
J Neurooncol; 2017 Jan; 131(2):377-384. PubMed ID: 27826681
[TBL] [Abstract][Full Text] [Related]
45. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
[TBL] [Abstract][Full Text] [Related]
46. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
Martins EP; Gonçalves CS; Pojo M; Carvalho R; Ribeiro AS; Miranda-Gonçalves V; Taipa R; Pardal F; Pinto AA; Custódia C; Faria CC; Baltazar F; Sousa N; Paredes J; Costa BM
Mol Oncol; 2022 Jul; 16(14):2611-2631. PubMed ID: 34919784
[TBL] [Abstract][Full Text] [Related]
47. Somatic CPEB4 and CPEB1 genes mutations spectrum on the prognostic predictive accuracy in patients with high-grade glioma and their clinical significance.
Boustani MR; Mehrabi F; Yahaghi E; Khoshnood RJ; Shahmohammadi M; Darian EK; Goudarzi PK
J Neurol Sci; 2016 Apr; 363():80-3. PubMed ID: 27000226
[TBL] [Abstract][Full Text] [Related]
48. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.
Lu VM; O'Connor KP; Shah AH; Eichberg DG; Luther EM; Komotar RJ; Ivan ME
J Neurooncol; 2020 Jun; 148(2):221-229. PubMed ID: 32385699
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic delay and survival in high-grade gliomas - evidence of the 'waiting time paradox'?
Aggarwal A; Herz N; Campbell P; Arkush L; Short S; Rees J
Br J Neurosurg; 2015; 29(4):520-3. PubMed ID: 25738427
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of microRNA-124 predicts poor prognosis in glioma patients.
Chen T; Wang XY; Li C; Xu SJ
Neurol Sci; 2015 Jan; 36(1):131-5. PubMed ID: 25112530
[TBL] [Abstract][Full Text] [Related]
51. An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals.
Nijaguna MB; Patil V; Hegde AS; Chandramouli BA; Arivazhagan A; Santosh V; Somasundaram K
PLoS One; 2015; 10(9):e0137524. PubMed ID: 26390214
[TBL] [Abstract][Full Text] [Related]
52. MicroRNA-210 overexpression predicts poorer prognosis in glioma patients.
Lai NS; Dong QS; Ding H; Miao ZL; Lin YC
J Clin Neurosci; 2014 May; 21(5):755-60. PubMed ID: 24382515
[TBL] [Abstract][Full Text] [Related]
53. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
[TBL] [Abstract][Full Text] [Related]
54. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
[TBL] [Abstract][Full Text] [Related]
55. Identification of diagnostic serum protein profiles of glioblastoma patients.
Elstner A; Stockhammer F; Nguyen-Dobinsky TN; Nguyen QL; Pilgermann I; Gill A; Guhr A; Zhang T; von Eckardstein K; Picht T; Veelken J; Martuza RL; von Deimling A; Kurtz A
J Neurooncol; 2011 Mar; 102(1):71-80. PubMed ID: 20617365
[TBL] [Abstract][Full Text] [Related]
56. MUC17 mutations and methylation are associated with poor prognosis in adult-type diffuse glioma patients.
Machado GC; Ferrer VP
J Neurol Sci; 2023 Sep; 452():120762. PubMed ID: 37562166
[TBL] [Abstract][Full Text] [Related]
57. Pre- and early postoperative GFAP serum levels in glioma and brain metastases.
Baumgarten P; Quick-Weller J; Gessler F; Wagner M; Tichy J; Forster MT; Foerch C; Seifert V; Mittelbronn M; Senft C
J Neurooncol; 2018 Sep; 139(3):541-546. PubMed ID: 29797180
[TBL] [Abstract][Full Text] [Related]
58. Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival.
Weng W; Chen X; Gong S; Guo L; Zhang X
Neurol Res; 2018 Nov; 40(11):917-922. PubMed ID: 30074469
[TBL] [Abstract][Full Text] [Related]
59. MRI and thallium-201 SPECT in the prediction of survival in glioma.
Vos MJ; Berkhof J; Hoekstra OS; Bosma I; Sizoo EM; Heimans JJ; Reijneveld JC; Sanchez E; Lagerwaard FJ; Buter J; Noske DP; Postma TJ
Neuroradiology; 2012 Jun; 54(6):539-46. PubMed ID: 21755329
[TBL] [Abstract][Full Text] [Related]
60. The prognosis of glioblastoma: a large, multifactorial study.
Luo C; Song K; Wu S; Hameed NUF; Kudulaiti N; Xu H; Qin ZY; Wu JS
Br J Neurosurg; 2021 Oct; 35(5):555-561. PubMed ID: 34236262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
